Law360 (June 25, 2020, 6:19 PM EDT) — Investors accusing CBD drugmaker Zynerba Pharmaceuticals of withholding worrisome clinical trial results from the public have told a Pennsylvania federal court that the company can’t beat their proposed class action by relying on its own self-serving interpretations of the data.
The investors said Wednesday that Zynerba’s continued pursuit of U.S. Food and Drug Administration approval for its anti-seizure CBD patch Zygel is irrelevant to its silence on the troubling initial results, which sent the company’s stock plummeting by 22% once they were revealed.
“That Zynerba continues to develop Zygel and may ultimately receive FDA approval and commercialize its only therapy under…
Recent Comments